4D Molecular Therapeutics: Market Expects Wet AMD Gene Therapy Failure - I'm Not So Sure

Core Insights - 4D Molecular Therapeutics (NASDAQ: FDMT) experienced a significant share price decline of nearly 50%, dropping from approximately $27 to $14 following the release of management data [1] Group 1: Company Overview - 4D Molecular Therapeutics is based in Emeryville, California and operates in the biotech sector [1] - The company is part of a broader investment group focused on biotech, healthcare, and pharma, providing insights and forecasts for major pharmaceutical companies [1] Group 2: Market Analysis - The investment group offers detailed financial models, product sales forecasts, and market analysis, catering to both novice and experienced biotech investors [1] - The group emphasizes the importance of identifying catalysts for investment decisions, including buy and sell ratings [1]